Plain-English translation of NCT07733830 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether the order in which you receive treatments makes a difference for advanced esophageal cancer. You'll receive a combination of chemotherapy drugs, radiation therapy, and an immunotherapy medication called — but the study compares two different sequences to see which order works best. Researchers want to learn if starting with the medication before radiation is more effective than starting with radiation first.
Currently, doctors treat advanced esophageal cancer with a combination of chemotherapy and radiation, but it's not clear whether adding immunotherapy at the beginning or at the end produces better results. This trial will help doctors understand the best timing and order of these treatments to help patients live longer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two treatment groups. Both groups receive the same total treatments — chemotherapy, radiation to the chest, and immunotherapy infusions — but in different orders. Group A starts with 2 cycles of chemotherapy plus the immunotherapy medication, then receives radiation combined with chemotherapy, then continues the medication. Group B starts directly with radiation combined with chemotherapy, then receives the medication. Either way, you'll have regular clinic visits for infusions (every 3 weeks) and monitoring scans over several months to track how well the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China